Across TCGA pan-cancer cohorts, RPL37P4 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RPL37P4’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where RPL37P4 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL37P4 is over-expressed in tumor.
BRCA and HNSC are the cancer types where RPL37P4 tumor–normal differential expression is most reproducible.